Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles
- PMID: 20820872
- DOI: 10.1007/s11060-010-0369-4
Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles
Abstract
Malignant gliomas are the most common subtype of primary central nervous system (CNS) tumors. Their pathological classification, however, remains subjective, stimulating researchers to actively seek objective molecular markers to discover alternative and more reproducible tools for improved subtypification. Herein, we present a global survey of genomic alterations in oligodendroglial tumors (OT). Genetic and epigenetic alterations identified in this study are correlated with OT molecular groups we have recently reported: a neurogenic group composed of tumors with loss of heterozygosity (LOH) at 1p-19q, IDH1 mutations, and MGMT promoter methylation, showing good prognosis; an intermediate group, presenting TP53 mutations or LOH at 17p, IDH1 mutations, and GSTP1 promoter methylation; and a proliferative group, presenting major genetic alterations (LOH at 10q, EGFR amplification, and CDKN2A/ARF deletion) and poor prognosis. These results allowed us to refine our molecular characterization associated with prognosis, referring exclusively to oligodendroglial tumors.
Similar articles
-
Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.J Neurooncol. 2009 Dec;95(3):343-354. doi: 10.1007/s11060-009-9944-y. Epub 2009 Jul 12. J Neurooncol. 2009. PMID: 19597701
-
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.Clin Cancer Res. 2005 Feb 1;11(3):1119-28. Clin Cancer Res. 2005. PMID: 15709179
-
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.Clin Cancer Res. 2002 Jan;8(1):196-201. Clin Cancer Res. 2002. PMID: 11801559
-
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Neurosurgery. 2010. PMID: 21107199 Review.
-
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89. doi: 10.1093/jnen/64.6.479. J Neuropathol Exp Neurol. 2005. PMID: 15977639 Review.
Cited by
-
Frequency and Prognostic Impact of CDKN2A/B Alteration in Oligodendrogliomas: Systematic Review and Meta-analysis.Neurol Med Chir (Tokyo). 2024 Dec 15;64(12):442-450. doi: 10.2176/jns-nmc.2024-0105. Epub 2024 Oct 22. Neurol Med Chir (Tokyo). 2024. PMID: 39443123 Free PMC article.
-
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.PLoS One. 2013 Jun 24;8(6):e67139. doi: 10.1371/journal.pone.0067139. Print 2013. PLoS One. 2013. PMID: 23826216 Free PMC article.
-
Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.Sci Rep. 2023 Apr 25;13(1):6761. doi: 10.1038/s41598-023-32153-y. Sci Rep. 2023. PMID: 37185778 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous